ARK Investment Management LLC boosted its holdings in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 7.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,618,871 shares of the company's stock after purchasing an additional 186,040 shares during the quarter. ARK Investment Management LLC owned about 4.23% of COMPASS Pathways worth $22,915,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. UBS Group AG boosted its holdings in shares of COMPASS Pathways by 249.1% in the fourth quarter. UBS Group AG now owns 4,291 shares of the company's stock valued at $34,000 after acquiring an additional 3,062 shares during the period. Advisor Group Holdings Inc. boosted its holdings in shares of COMPASS Pathways by 129.7% in the fourth quarter. Advisor Group Holdings Inc. now owns 5,406 shares of the company's stock valued at $43,000 after acquiring an additional 3,052 shares during the period. Quantbot Technologies LP boosted its holdings in shares of COMPASS Pathways by 156.8% in the first quarter. Quantbot Technologies LP now owns 3,338 shares of the company's stock valued at $43,000 after acquiring an additional 2,038 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of COMPASS Pathways by 229.6% in the third quarter. Tower Research Capital LLC TRC now owns 7,847 shares of the company's stock valued at $58,000 after acquiring an additional 5,466 shares during the period. Finally, Bailard Inc. acquired a new stake in shares of COMPASS Pathways in the third quarter valued at approximately $88,000. 46.19% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms have recently commented on CMPS. Deutsche Bank Aktiengesellschaft initiated coverage on COMPASS Pathways in a research note on Tuesday, December 12th. They set a "buy" rating and a $16.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $120.00 price target on shares of COMPASS Pathways in a research note on Friday, March 1st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $49.00.
Get Our Latest Analysis on COMPASS Pathways
Insiders Place Their Bets
In related news, Director Ekaterina Malievskaia sold 11,862 shares of the firm's stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $10.06, for a total transaction of $119,331.72. Following the completion of the transaction, the director now owns 4,110,338 shares in the company, valued at approximately $41,350,000.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Ekaterina Malievskaia sold 11,862 shares of COMPASS Pathways stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $10.06, for a total value of $119,331.72. Following the completion of the sale, the director now directly owns 4,110,338 shares in the company, valued at $41,350,000.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director George Jay Goldsmith sold 15,740 shares of the firm's stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $10.58, for a total transaction of $166,529.20. Following the completion of the transaction, the director now directly owns 4,079,107 shares in the company, valued at approximately $43,156,952.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 111,175 shares of company stock worth $1,058,199. 23.99% of the stock is currently owned by company insiders.
COMPASS Pathways Price Performance
CMPS stock traded down $1.18 during trading hours on Thursday, hitting $8.32. 3,561,762 shares of the stock traded hands, compared to its average volume of 722,174. The stock has a 50-day simple moving average of $10.34 and a 200 day simple moving average of $8.28. COMPASS Pathways plc has a one year low of $5.01 and a one year high of $12.75. The company has a market cap of $515.34 million, a P/E ratio of -3.72 and a beta of 2.52. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.14.
COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.16). Equities analysts forecast that COMPASS Pathways plc will post -2.45 earnings per share for the current year.
COMPASS Pathways Company Profile
(
Free Report)
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Read More
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
